The baculovirus-insect cell system can produce large quantities of complex protein in a short period of time.
Interactions between biologic drug products and the components of prefilled syringes can cause protein aggregation, but there are alternative materials that can help mitigate this problem.
Industry experts spoke to BioPharm International about the key considerations in the development of a drug-delivery device for a biologic drug, the importance of human factors engineering, the advantages of prefilled syringes, and the challenges in the manufacture of these devices.
Understanding and preventing protein aggregation is crucial to ensuring product quality and patient safety.
Experts discuss the advances in single-use technology for downstream bioprocessing applications.
Experts discuss the advances in single-use technology for downstream bioprocessing applications.
Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.
Review the importance of characterization studies during biosimilars development and related analytical methods.
Scientists at A*STAR's Genome Institute of Singapore (GIS) have identified genes that could be potential targets for anticancer agents in the treatment of aggressive breast cancer.
Adaptimmune has opened a Phase I/IIa ovarian cancer trial to evaluate its genetically engineered T cell treatment, with enhanced antitumor activity.